Skip to content
Official representative office in Russia · Sinopec Yizheng Chemical Fibre Co., Ltd.
UHMWPE 09 / 09

Medical yarns and implants

A separate quality and regulatory framework

Stage one is selling a partner’s finished suture with needle to study the market. The next stage is in-house production from medical UHMWPE Y series. Implants remain a separate long-term prospect.

Sterile white medical yarn on a spool in a laboratory

01 — ROLE IN THE PRODUCT

How each material works

The material is selected by its function in the structure. The same product may require different fibres depending on the environment and load.

UHMWPE

Finished product first, then in-house production

Finished suture with needle validates demand and the business model before production investment. Y series is considered as raw material for the next stage; its documents and suitability need separate verification.

02 — APPLICATIONS

Where the yarn is used

A

Finished suture

Sterile partner suture with needle — the starting product for studying the range, buyers and sales economics.

B

In-house production

The next stage: suture production from Y-series fibre after studying the process with partners.

C

Medical constructions

Yarn and textile components after assessment of intended use and body contact.

D

Implants

A separate long-term prospect, including joint components; not part of the initial demonstration launch.

03 — VISUAL GUIDE

Yarn inside the product

The illustrations show where the high-performance material sits and what it does. These are application diagrams, not photographs of serial products.

04 — CATALOGUE GUIDE

Supply forms and series

A starting point for a technical inquiry, not a ready-made pilot specification.

UHMWPE
  • Finished suture with needle in original packaging
  • Y: 25D / 30D / 50D
  • 100D / 150D / 200D
  • 300D / 400D / 600D
  • Batch, clean line, packaging and sterilisation according to documents

What the material offers

  • A finished product allows the market to be tested first
  • A special range of fine medical filaments
  • A controlled clean line is claimed
  • Production can be studied with partners in stages

Mandatory checks

  • In-house production is a next stage, not an operating asset
  • FDA endpoint requirements do not mean FDA certification or approval
  • Fibre documents do not replace medical-device registration
  • Implants require a separate complex project

05 — SELECTION AND PILOT

Four inputs for a technical inquiry

The more precise the inputs, the fewer unnecessary samples and the faster the comparison with the incumbent material.

StageFinished suture or future in-house production
RangeNeedle, yarn, size, packaging and sterilisation
QualityISO 13485, COA, cleanliness and batch traceability
MarketBuyer, sales channel, price, volume and repeat order

Questions for the product manufacturer

Which manufacturer and range of finished sutures are available?

Record the answer in the technical specification together with the control material, pilot volume, test method and acceptance criteria.

Which needle, yarn and size combinations do buyers need?

Record the answer in the technical specification together with the control material, pilot volume, test method and acceptance criteria.

Which packaging and sterilisation are confirmed by documents?

Record the answer in the technical specification together with the control material, pilot volume, test method and acceptance criteria.

Can we visit the partner’s production and study the process before our own launch?

Record the answer in the technical specification together with the control material, pilot volume, test method and acceptance criteria.

Next step

A sample for your design

Open the inquiry form and specify the product, requirements and approximate pilot volume. Lab-test samples are free.

Prepare technical inquiry